RxDoctor Payments Data

Christen Greuel, DO

Family Medicine · Claremore, OKNPI 1740712348

Payments from drug & device makers

$8,754in general payments, 2019–2025

Across 485 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$821
  • Lilly USA, LLC$806
  • AbbVie$732
  • AstraZeneca$730
  • Amgen$573
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$8,754100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,754 in reported general payments places this provider in the 90th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$19,074
Medicare patients
43
Services billed
751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide70$93,958
JardianceEmpagliflozin63$66,698
OzempicSemaglutide48$50,929
JanuviaSitagliptin Phosphate41$38,803
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$35,125
TrulicityDulaglutide17$32,285
RybelsusSemaglutide22$31,758
EliquisApixaban36$27,022
Tresiba Flextouch U-200Insulin Degludec22$26,399
FarxigaDapagliflozin Propanediol16$22,778
Breztri AerosphereBudesonide/Glycopyr/Formoterol28$21,673
XareltoRivaroxaban13$17,130
Repatha SureclickEvolocumab11$6,201
BelsomraSuvorexant12$5,343
Aripiprazole60$4,746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$806$126,24387 claims
Novo NordiskOzempic, Rybelsus$1,452$82,68870 claims
Boehringer IngelheimJardiance$374$66,69863 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$730$47,40755 claims
MerckJanuvia, Belsomra$289$44,14653 claims
GSKTrelegy Ellipta$346$35,12552 claims
PfizerEliquis$821$27,02236 claims
Johnson & JohnsonXarelto$225$17,13013 claims
AbbVieSynthroid$732$1,10021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Claremore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →